By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New COPD inhaler approved for use in UK

A new drug and inhaler combination has received marketing authorisation as a treatment for chronic obstructive pulmonary disease.

The European Medicines Agency has approved Almirall’s aclidinium bromide inhaler (Eklira Genuair) for twice daily use as a means of relieving symptoms in adult patients with COPD.

The drug component, aclidinium (Eklira), is a new type of long-acting muscarinic antagonist therapy. It is delivered by the Genuair multi-dose dry powder inhaler. 

It reduced breathlessness and improved quality of life, when compared to placebo in trials, with data showing the significant bronchodilation achieved on day one of use was still in evidence after six months of treatment.

According to its manufacturer, patients treated with the new drug also required less rescue medication than patients treated with placebo.

Eklira Genuair provides relief within 30 minutes, and offers “clinically meaningful improvements in lung function” over 12 hours following each morning and evening administration, Almirall said.

The drug and inhaler will cost £28.60.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!